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a  b  s  t  r  a  c  t
This  paper  describes  a  decisional  tool  that  is  designed  to  identify  cost-effective  process  designs  for  drug
screening  products  derived  from  human  induced  pluripotent  stem  cells  (hiPSC).  The  decisional  tool  com-
prises a  bioprocess  economics  model  linked  to  a search  algorithm  to  assess  the  ﬁnancial  impact  of manual
and automated  bioprocessing  strategies  that use  2D-planar  tissue  culture  technologies.  The  tool  was
applied  to a case  study  that examines  the production  of patient-speciﬁc  iPSC-derived  neurons  for  drug
screening.  The  production  strategies  were  compared  across  three  analytical  drug screening  methods,  each
requiring  cell  production  at a  distinct  scale  (manual  patch-clamp  analysis,  high  throughput  screening  and
plate-based  pharmacology),  as well  as different  annual  cell  line  utilization  requirements  (‘throughputs’)
(between  10  and  100  lines)  so  as  to represent  different  industry  scenarios.  The  tool  determined  the  crit-
ical  cell  line throughput  where  the  most  cost-effective  production  strategy  switched  from  the manualptimisation
ioprocess design
cale up
to  automated  workﬂow.  The  key  process  economics  driver was  the number  of iPSC  expansion  stages
required.  Stochastic  modelling  of the  bioprocess  illustrated  that  the  automated  was  more  robust  than
the  manual  workﬂow  in  the  scenarios  investigated.  The  tool  predicted  the  level  of  performance  improve-
ments  required  in iPSC  expansion  and  differentiation  as  well  as  reductions  in  indirect  costs  and  media
costs  so  as  to  achieve  an acceptable  cost  of  goods  (COG).
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
The advent of hiPSC technology [1] has provided an opportu-
ity to revolutionise modern medicine. Aside from their potential
se in the cell therapy sector as clinical grade raw material to
roduce treatments for a variety of disorders with unmet clin-
cal needs, hiPSCs also offer a more near term application as a
ool with which current drug discovery, phenotypic screens, and
afety testing programmes might be qualitatively improved [2–5].Please cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
his article investigates the production of patient-speciﬁc hiPS-cell
ines, namely a cell line which is derived from a single patient
n order to capture their individual genotype and phenotype.
Abbreviations: COG, cost of goods; CTS, CompacT SelecTTM automated cell cul-
ure machine; FCI, ﬁxed capital investment; hPSC, human pluripotent stem cell; HTS,
igh throughput screening; iPSC, induced pluripotent stem cell; PCA, patch-clamp
nalysis; NCE, novel chemical entity; PBP, plate-based pharmacological analysis;
SC, pluripotent stem cell.
∗ Corresponding author.
E-mail address: s.farid@ucl.ac.uk (S.S. Farid).
ttp://dx.doi.org/10.1016/j.bej.2015.09.024
369-703X/© 2015 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
Manufacture of patient-speciﬁc cell lines will require scale-out of
the process, whereby the manufacturing scale or lot size is kept
constant and replicated for each cell line. In contrast, manufac-
ture of non patient-speciﬁc cell lines can beneﬁt from scale-up,
whereby the manufacturing scale or lot size is increased when
larger demands of a cell line are required (see Fig. 1a). Non patient-
speciﬁc cell lines are more likely to be used for purposes that are
independent of the speciﬁc genotype or phenotype of a cell.
In drug development, many pre-clinical testing platforms based
on animal species prove to be of limited predictive value due to fun-
damental biochemical, physiological and genomic variations from
humans [6–8]. hiPSC-differentiated somatic cells offer an alter-
native, humanised platform for pre-clinical efﬁcacy and toxicity
studies for novel therapeutics in development [9]. They also afford
a predictive platform at the preclinical to clinical interface in, for
example, safety vigilance of novel therapeutics in development,
pinpointing drug responders from non-responders and stratifyingPSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
patients into treatment groups in patient cohorts. Furthermore, the
ability of patient-speciﬁc hiPSC-derived cells to model genetic and
epigenetic variations of a broad spectrum population may  also aug-
ment phase I/II clinical trials via the demonstration of a drug’s safety
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ARTICLE IN PRESSG ModelBEJ-6302; No. of Pages 14
2 M. Jenkins et al. / Biochemical Engineering Journal xxx (2015) xxx–xxx
Fig. 1. (a) Outline of process techniques for patient-speciﬁc cell lines and non-speciﬁc cell lines. The bioprocess for a single patient-speciﬁc cell line is scaled-out to achieve
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( higher throughput. Non-speciﬁc bioprocesses are scaled-up to achieve a higher th
lonal  processing is employed following cellular reprogramming, therefore the tec
f  the scale of the bioprocess.
nd efﬁcacy within a target population in vitro. Patient-speciﬁc
iPSC-derived cells may  be of particular use in the assessment of
CEs where the degree of efﬁcacy observed within a cohort may
epend upon a speciﬁc geno- or phenotype [10]. In this manner
hey have the potential to lower the time, costs, and risks associated
ith committing a drug to clinical trials. The cost of bringing a new
rug to market is currently estimated to be US$1.2bn—US$1.7bn.
hen juxtaposed with a clinical attrition rate that can be close
o 90% (phase I to approval) [11], such an expensive and complex
evelopment cycle has caused drug developers to display caution
hen committing candidate therapies to clinical trials [12,13].
hiPSC-derived cell types have faced challenges in their imple-
entation owing partly to key issues associated with their
roduction at large scale. Many current iPSC manufacturing pro-
ocols are based upon planar, 2-D culture vessels due to their
ffordability and simplicity [14]. However, lack of scalability owing
o limitations in surface area to volume ratio and the inability to
onduct online process monitoring are major drawbacks to many 2-
 culture systems, as is their labour-intensive nature, which limits
heir throughput and applicability to larger scale processes [15,16].
on patient-speciﬁc cell processing may  beneﬁt from recent iPSC
ioprocessing advances, such as single-use bioreactors (SUBs) and
icrocarriers, which offer both greater potential for scale-up and
n enhanced degree of containment in comparison to planar vessels
17–22]. However, patient-speciﬁc bioprocesses are not amenable
o scale-up and will likely depend upon planar culture technologies,
hich may  be useful when producing cell populations numberingPlease cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
n the low millions [23,24]. Automation systems designed to accom-
odate planar culture vessels, such as the CompacT SelecTTM (CTS)
Sartorius, Royston, UK), have the potential to reduce the labourput. (b) An overview of the bioprocess strategies considered within this case study.
gy used to process each donor sample remains constant until this point, regardless
requirements, possible points of contamination, and to improve the
reliability associated with autologous hiPSC bioprocessing [25–27].
Such systems could be implemented to help achieve large-scale
manufacture of patient-speciﬁc stem cell products.
The biopharmaceutical sector has beneﬁtted from the use of
decisional tools that are able to evaluate alternative process designs
in silico in order to achieve cost-effective process design and equip-
ment selection [28–32]. As a nascent ﬁeld, hiPSC processing is faced
with a lack of consensus as to optimal process designs and scale-
up/out strategies. Decisional tools similar to those applied to the
biopharmaceutical sector can therefore prove useful for identifying
key economic drivers and technical innovations required to bridge
the gaps constraining widespread application of hiPSC-derived
cells. There are only a limited number of studies investigating
the impact of process design on manufacturing COG within the
stem cell sector. Previous analyses have provided estimates of the
current limitations [15,33] and relative cost of PSC processing tech-
nologies, including the use of commercially available ﬂow-sheeting
software (SuperPro Designer, Intelligen Inc., NJ, USA) to evaluate
the economic potential of large-scale iPSC-derived cell bioprocess
designs [34]. For other cell types, for example mesenchymal stro-
mal  cells for therapy, others have illustrated how a decisional tool
can be developed to determine the scales at which microcarriers
in SUBs becomes preferable to planar processing platforms during
the expansion phase [16].
In this paper, an integrated decisional tool that combines both
bioprocess economic modelling and optimisation of the manufac-PSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
ture of patient-speciﬁc iPSC-derived neurons for use as a tool in the
screening of NCEs is described. The bioprocess economics model
and integrated brute-force search algorithm are designed to iden-
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Table 1
Methods and feeding regimes for bioprocess unit operations.
Unit operation Method Feeding regime
Erythroblast expansion
& enrichment
Culture-based
expansion and
puriﬁcation of
erythroblasts
Daily media
replacement
Cellular
reprogramming
Sendai virus
transduction of
Yamanaka factors
Media replacement
every two days during
transduction
Daily media
replacement during
iPSC generation period
iPSC  expansion Monolayer
10% of viable cells
banked to safeguard
against process failure
during differentiation
Daily media
replacement
Differentiation Monolayer, small
molecule based
Twice weekly media
replacement
Table 2
Labour tasks and their duration.
Labour task Time required (h) (ti)
Media preparation 1
Cell harvest 0.75
Cell seeding 0.5
Media replacement 0.5
Viral transduction 1.5
CompacT SelecT setup 2
CompacT SelecT termination 2ARTICLEEJ-6302; No. of Pages 14
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ify the process design that minimises the COG. The use of speciﬁed
utomation equipment such as the CTS for iPSC cell bioprocess-
ng and its impact upon the overall COG is also evaluated as an
lternative to existing, manual bioprocessing options (Fig. 1b).
. Tool description
A decisional tool was developed to evaluate the COG associ-
ted with different bioprocess strategies and equipment sizing of
echnologies to be used during the manufacture of patient-speciﬁc
PSC-derived cell lines. It comprises a bioprocess economics model,
n information database, and an integrated brute-force search
lgorithm. The tool was constructed in and is implemented via
icrosoft Excel (Microsoft Corporation, WA,  USA) and the Visual
asic for Applications tool (VBA) (Microsoft Corporation). A brute-
orce search algorithm generates possible process conﬁgurations,
rom a database of speciﬁed process technologies, to be evalu-
ted by the bioprocess economics model. Microsoft Excel was used
ecause of its dual functionality in being able to act as a database
or model inputs and outputs in addition to a tool by which to
onstruct a bioprocess economics model. VBA’s simple integration
ith MS  Excel makes it ideal for efﬁciently linking the database and
ioprocess economics model to the optimisation algorithm.
.1. Deterministic bioprocess economics model
The bioprocess economics model evaluates the COG per cell
ine for different bioprocess conﬁgurations. A critical feature of
atient-speciﬁc cell bioprocesses is that they dictate the adoption
f a scale-out, rather than scale-up, approach to process design and
evelopment as throughput increases. Therefore, separate process-
ng of individual donor products is assumed throughout the model,
.e. separate culture vessels are used for cells from separate donors.
A key parameter when evaluating equipment sizing strategies
s the type of technology to be used within each unit operation
nd the number of units required to process the required number
f cells from each donor sample. For a given cell output, P (cells
er cell line), the number of units (ucon,i,j) required of a particular
echnology, j, for a given unit operation, i, is calculated as;
con,i,j =
Pi
dh,i × aj
(1)
here aj is the available surface area per unit for each technology
nd dh,i represents the harvest density (cells/cm2) for a given unit
peration.
Determining the number of units for a given technology allows
he bioprocess economics model to draw on information stored in
he database so as to evaluate the COG/cell line via a cascade of
quations. Thus, the bioprocess economics model is able to calcu-
ate the total COG/cell line:
COG
Cell line
=
(

i
[
Cannmat,i + Cannlab,i
])
+
Cannindirect,
Dann
(2)
here Cmat, i and Clab, i are the costs of raw materials and labour,
r the direct costs, associated with each individual unit operation
ithin the bioprocess. Dann is the annual throughput (cell lines
roduced per year). Direct costs attributed to a speciﬁc unit oper-Please cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
tion are calculated separately for each individual unit operation,
hereas indirect costs are calculated on a whole bioprocess basis
ecause ﬁxed equipment may  be shared between multiple unit
perations.Culture check (manual) 0.5
Culture check (automated) 0.25
Material costs per unit operation, Cannmat,i, are calculated as a func-
tion of the utilisation of chemicals (e.g. media) and consumables
(e.g. plastic culture vessels):
Cannmat,i = ui,j
[
Vmed,j × ai,j × Cmed,i
]
+ Cj (3)
where Vmed, j is the media utilisation (mL/cm2), Cmed, i the cost of
media used within a particular unit operation i and Cj the price per
unit associated with a given technology j.
Assumptions regarding media replacement regimes, which are
taken into account by the deterministic model, can be found in
Table 1.
Labour costs are calculated as a function of the time required to
carry out tasks speciﬁc to each unit operation of the iPSC biopro-
cess (ti). It is assumed that for each technology type an operator
could handle a given number of units, ωj , within this time period.
Therefore:
Cannlab,i =
(
uij
ωj
)
× ti × w (4)
where w represents the hourly cost of labour. Individual labour
tasks and their durations can be found in Table 2.
2.1.1. Indirect costs
Fixed capital investment costs are calculated using an adjusted
Lang factor developed at UCL for estimating capital investment
costs associated with disposable facilities [32]. The Lang factor
method assigns a proportionality constant to the total equipment
purchase cost in order to provide a facility capital investment (FCI)
estimate [35]. The Lang factor accounts for items that contributePSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
to the cost to build the facility such as pipework, instrumentation,
building works, construction, commissioning and validation.
FCI = Flang × Cfixed (5)
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here Cﬁxed represents the cost of any ﬁxed equipment within the
ioprocess facility. The ﬁxed equipment costs are calculated thus:
fixed =
n

i=1
(
 ui,x
˛inc,i
 × Cinc + 
ui,x
˛bsc,i
 × Cbsc + 
ui,x
˛CTS,i
 × CCTS
)
(6)
here ˛inc, ˛bsc and ˛CTS are the capacities of incubators, biosafety
abinets and CTS (when automated processing is employed),
espectively, with regards to a particular technology, i, during the
ioprocess. Cinc, Cbsc and CCTSt refer to the cost of individual units of
xed equipment used within the bioprocess. It was assumed that
iosafety cabinets could only be used by one operator at a time.
In this study the main annual indirect cost considered was  the
epreciation, calculated by dividing ﬁxed capital investment costs
y the depreciation period, tdep, representing the lifespan of ﬁxed
quipment:
ann
indirect =
Cfixed
tdep
(7)
ithin unit operations such as iPSC expansion, where multi-
le expansion stages are required, different technologies may  be
referable for each subsequent stage. Therefore, each expansion
tage was treated as a de facto unit operation and logic constraints
ere put in place such that technologies in preliminary expansion
tages were smaller, or equal in size to candidate technologies in
ubsequent ones (i.e. ai,j−1 ≤ ai,j). This is in order to abide by stan-
ard processing protocols, whereby the size of the equipment used
n the expansion stages of stem cell culture is traditionally scaled
p as cell populations continue to grow.
Additionally, process designs returning ﬁxed equipment util-
sation values of greater than 95% were discarded from results.
his is to avoid utilisation of such equipment exceeding capacity
n the event where additional vessels might be required owing to
ariations in processing parameters.
.2. Brute-force search algorithm
The brute-force algorithm has been designed to determine opti-
al  equipment sizing for each unit operation within the process
ia a procedure which examines all possible bioprocess designs
ccording to process technologies housed in the database.
The bioprocess economics model described above is able to cal-
ulate the COG per cell line for a speciﬁed process conﬁguration
sing technologies of a given size. A brute-force search algorithm
evelops all of the available process designs for the bioprocess eco-
omics model to quantify on the basis of COG per cell line. This
ioprocess economics model then generates COG data for the array
f alternative process designs. The output data is then screened in
rder to identify the bioprocess design that minimises COG. Fig. 2
llustrates how the optimisation algorithm works alongside the bio-
rocess economics model to achieve cost-effective process design.
.3. Stochastic modelling
The deterministic COG provided by the tool described in the
revious section allowed identiﬁcation of the optimal bioprocess
esign and equipment sizing within each unit operation of the
ioprocess. However, deterministic analyses cannot offer an evalu-
tion of the robustness of iPSC bioprocessing strategies. Achieving
rocess reproducibility is a signiﬁcant challenge within stem cell
ioprocessing, particularly when manual processing strategies arePlease cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
mployed [14,25,26]. Furthermore, accounting for donor-to-donor
ariability also presents a unique challenge. The Monte Carlo sim-
lation method was applied to the decisional tool to provide
tochastic modelling of the iPSC bioprocess in order to quantify PRESS
ring Journal xxx (2015) xxx–xxx
the robustness and reproducibility of automated and manual iPSC
bioprocess strategies. Adjusting input parameters also allowed the
model to capture variations in COG that arise as a result of donor-
to-donor variability within key process parameters.
Previously published reports have suggested that manual
bioprocesses result in greater variability than those which are auto-
mated [26,37]. Hence, narrower distributions have been assigned
for the automated iPSC bioprocess to reﬂect this (input probability
distributions are shown in Table 6). Probability ranges have been
corroborated with industry experts to ensure they are representa-
tive.
The Monte Carlo simulation method was  used to carry out
probability-based economic assessment of the manual and auto-
mated bioprocess. During the Monte Carlo simulation, the process
ﬂow-sheet was held constant. The culture vessels tested within the
Monte Carlo analysis were those selected as the most cost-effective
by the brute-force search algorithm. In order to ensure that the tar-
get cell population size was  achieved for each donor cell-line, the
direct resources and ﬁxed equipment required were re-calculated
during each Monte Carlo simulation to account for the variations
in process parameters as a result of the assigned input distribu-
tions. Future improvements to screening methods may  allow one to
identify single-nuclear polymorphisms (SNPs) in the original donor
sample that correlate with bioprocess performance. In future, this
method could allow the likely performance of a donor’s iPSCs to
be ascertained prior to the bioprocess. Thus, prospective re-sizing
of the bioprocess may  be a feasible option; therefore, the number
of culture vessels has been left as a variable in the Monte Carlo
analysis.
3. Case study setup
3.1. Tool application
A representative case study was  developed in partnership with
Pﬁzer’s Neuroscience and Pain Research Unit (Great Abington,
Cambridge, UK) that focused on optimising the production of
patient-speciﬁc iPSC-derived cells for drug screening. Speciﬁcally, it
addressed the generation of iPSC-derived neurons to supply patient
drug responder versus non-responder, “trial in a dish” screening
platforms with which to augment clinical trials for NCEs. It is esti-
mated that cell lines from 50 separate donors could be required to
run such a screening programme. To investigate the effect of scale-
out on the COG associated with the bioprocess, throughputs of 10,
50 & 100 cell lines per year were investigated by this study.
There are a variety of analytical methods by which to carry
out drug screening. Currently, the resting or active status of the
membrane potential in functional iPSC-derived neurons are ana-
lysed by patch-clamp analysis (PCA), a manual technique which
requires a small sample population of iPSC-derived neurons (105).
Whilst this is a data-rich analytical method, it samples only a small
number of cells and is therefore a poor representation of whole
cell populations [36]. Powerful, automated analytical techniques
such as high throughput screening (HTS) and plate-based phar-
macological analysis (PBP) are also available methods by which
to screen cells’ reactions to NCEs. These techniques require larger
sized cell populations (2 × 106 and 107 cell, respectively), but offer
high throughput analytical platforms. The level of scale-up required
of the bioprocess required to manufacture each individual cell line
is dependent on the analytical technique used for drug screening,
along with characteristics of different analytical techniques (Fig. 3).PSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
Two different manufacturing strategies were considered dur-
ing this case study; manual bioprocess techniques were evaluated
alongside an automated iPSC bioprocess, whereby iPSC expansion
and differentiation were carried out using the CompacT SelecT SC
ARTICLE IN PRESSG ModelBEJ-6302; No. of Pages 14
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Fig. 2. Tool schematic showing evaluative network used to identify the optimal bioprocess design, xoptimal.
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cig. 3. Cell population sizes of iPSC-derived neurons required to satisfy the demand
he  scale of the bioprocess required to produce cells for each analytical method. Th
Sartorius, Royston, UK). The decisional tool was applied primarily
n order to select the most cost-effective process design in both
nstances. However, process reproducibility in stem cell biopro-
essing is a signiﬁcant challenge. As such, stochastic modelling was
lso employed to ascertain the robustness of both manufacturing
trategies using the Monte Carlo simulation method.
.2. Process overview
The process ﬂowsheet used for the case study (Fig. 1) employs
rocessing of individual clones following the reprogramming stage;Please cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
s such, the preliminary unit operations are of a constant scale
egardless of the ﬁnal number of iPSC-derived neurons produced
rom each cell line. Therefore, the main focus of this case study
omprises the iPSC expansion and differentiation unit operations.ifferent analytical drug screening techniques. The required population size dictates
r panels illustrate graphically key characteristics of each analytical technique.
Further details regarding the methods used and feeding regimes
assumed for each unit operation can be found in Table 1. Media
changes are assumed to involve a full exchange of media within a
process vessel.
The planar technologies considered within the case study
included well plates (WP) as well as standard and compact multi-
layer versions of T-ﬂasks (T, cT, 3-F, 5-F) and stacked vessels (L-2,
L-5, cL-12). Their key input parameters are stored within the tool’s
database (Table 3). This data was  compiled using vendor websites
and consultation with industry experts so as to properly capture the
characteristics of each candidate technology. Key process and cost
assumptions are summarised (Tables 4 and 5) and where possible,PSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
these values have been compiled via a thorough review of available
literature on planar bioprocessing of iPSCs and their derivatives. All
assumptions listed in Tables 4 and 5 were then corroborated with
ARTICLE IN PRESSG ModelBEJ-6302; No. of Pages 14
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Table 3
Process technologies tested by the tool and their key performance parameters.
Technology
type
(i)
Surface area
(cm2/unit)
(ai)
Cost (£/unit)
(Ccon i)
Media
requirements
(mL/unit)
(Vreq i)
Max units per
operator
(ωop i)
Incubator
capacity
(double stack)
(ıinc i)
Requires BSC
cabinet
(Y/N)
CompacT
SelecT capacity
T-25 25 £1.54 7 4 100 Y –
T-75  75 £2.21 18.75 4 100 Y 90
T-175  175 £4.95 50 4 100 Y 90
T-225  225 £5.27 56.25 4 100 Y –
6-WPa 9.5 £2.10 2 24 600 Y –
24-WPa 1.9 £2.66 0.5 48 2400 Y –
L-2b 1272 £55.08 315 2 60 Y –
L-5b 3180 £180.49 787.5 2 24 Y –
cL-12c 6000 £287.69 1300 2 24 Y –
3-Fd 525 £10.20 150 – – N 90
5-Fe 875 £17.00 250 – – N 90
cTf 1720 £63.58 500 – – N 90
a Well plate.
b Multilayer planar vessels e.g. CellSTACK (Corning).
c Compact multilayer vessel e.g. 12-layer HYPERStack (Corning).
d 3-layer T-ﬂasks e.g. Triple Flask (Nunc) or Falcon Multi-Flask (Corning).
e 5-layer T-ﬂasks e.g. Falcon Multi-Flask (Corning).
f Compact multilayer ﬂask e.g. 10-layer HYPERFlask (Corning).
Table 4
Key process assumptions.
Unit operation (j) Seeding density (cells/cm2) Harvest density (cells/cm2) (dh,i) Yield/harvest yield/efﬁciency (%) Fold expansion
Erythroblast enrichment 1.5 × 105 3.2 × 105 25 (Yield) N/A
Erythroblast expansion 1.5 × 105 3.2 × 105 95 (harvest yield) 2
Reprogramming (transduction) 2.6 × 105 2.6 × 105 95 (harvest yield) N/A
Reprogramming (generation) 104 104
iPSC  expansion 4.2 × 104 3 × 105
Differentiation 3 × 105 3 × 105
Table 5
Key process cost parameters.
Cost Parameter Valuea
Media
Differentiation media £0.55–£0.67/mL
Expansion medium £0.43/mL
Reprogramming vector £664/donor
Labour £60/h
Fixed equipment
Incubator (Large) £11,890
Incubator (Small) £5,175
CompacT SelecT £550,000
Biosafety cabinet £11,390
Depreciation
period
10 Years
Lang factor
(manual bioprocess
strategy)
23.7
Lang factor
(automated
bioprocess
strategy)
16
u
i
i
w
t
p
i
b
a
m
aa Price ranges are provided where more than one type of media is used within a
nit operation.
ndustry experts to ensure they were representative. While sensible
nputs and assumptions were sought, the primary aim of the paper
as to demonstrate the application of the proposed methodology
o provide visibility of the cost structure and the most signiﬁcant
rocess economics drivers for iPSC generation for drug screen-
ng applications. Hence, the actual inputs and answers should notPlease cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
e seen as deﬁnitive but an illustration of how to approach such
n assessment. The risk of batch failure was also considered. The
anual bioprocess strategy was assumed to exhibit a higher prob-
bility of batch failure (4%) compared to the automated strategy0.5 (efﬁciency) N/A
90 (per passage) 7
35 (efﬁciency) N/A
(2%) given the greater human intervention and degree of open
processing in the manual strategy. Failure rates were assumed to
capture the worst-case scenario, i.e. failure occurs during the ﬁnal
stages of differentiation. Therefore, the direct costs of iPSC expan-
sion and differentiation for additional donor samples required due
to process failure were added to the ﬁnal COG  ﬁgure within the
deterministic model to account for additional processing as a result
of the batch failure rate. Only iPSC expansion and differentiation
were assumed to be repeated following a failed lot because of the
cell banking procedure in place.
4. Results and discussion
The decisional tool was used to assess the cost-effectiveness of
alternative bioprocess designs across a range of different scales
of production. A deterministic model was  developed in order to
carry out COG comparisons between different process designs and
sensitivity analyses were used to further investigate economic
drivers associated with the iPSC bioprocess. The tool was  then
adapted for stochastic modelling in order to evaluate the robust-
ness under uncertainty of automated and manual bioprocessing
strategies using the Monte Carlo simulation method.
4.1. Deterministic cost modelling
4.1.1. Optimal bioprocess designs across different scales and
throughputs
The optimal combination of process technologies for the ﬁnal
iPSC expansion stages and differentiation operation, for both thePSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
manual and automated bioprocess are depicted in Fig. 4. The num-
ber of iPSC-derived neurons produced per cell line is representative
of the size of cell populations needed to satisfy the demands of PCA,
HTS and PBP analysis (moving vertically from the top to the bottom
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Fig. 4. Matrices showing the optimal bioprocess conﬁguration for the ﬁnal stage
of expansion and differentiation for (a) manual bioprocess strategies and (b) auto-
mated bioprocess strategies across the range of scale investigated in this study.
Lighter shaded cells indicate cheaper COG per cell line relative to other bioprocess
d
p
o
f
i
h
p
F
o
v
aesigns shown in the matrices, where the lightest shade indicates the cheapest COG
er  cell line output value.
f the matrices). The cell population outputs per cell line required
or each of these analytical methods are shown in Fig. 3, and alsoPlease cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
n Fig. 4. Annual throughputs of 10, 50 and 100 cell populations
ave been shown to depict the effects of scale-out on optimal bio-
rocess design. The bioprocess throughput, in terms of cell lines
ig. 5. Direct cost breakdown for the optimal technologies at scales satisfying the demand
f  50 cell lines/yr for (a) the ﬁnal stage of expansion and (b) differentiation. Required iPSC
alues  on the y-axis have been assigned to maintain scales whereby data can be clearly se
re  labelled above the relevant columns. PRESS
ring Journal xxx (2015) xxx–xxx 7
produced per year, increases horizontally from left to right across
each matrix. The matrices show the optimal technology size and
the number of units required (in square brackets) per cell line for
each scale tested.
Depicting optimal technology sizing for manual bioprocessing
shows that as the size of cell populations produced increases, there
is a trend towards technologies with a larger surface area (Fig. 4a).
Larger technologies, which require fewer vessels, are selected as
the optimal bioprocess design. For example 2 × 2-layer CellSTACK
vessels (L-2) are preferred for the ﬁnal expansion stage when pro-
ducing 107 cells per cell line (for PBP), as opposed to 4 × T-75 ﬂasks
if 2 × 106 cells per cell line were to be produced (for HTS analysis).
Larger vessels are preferred when larger cell populations are pro-
duced when a manual bioprocess strategy is employed as depicted
by the direct cost breakdown for optimal technologies for the man-
ual bioprocess at different production scales at a throughput of 50
donor samples per year for the ﬁnal expansion stage and differen-
tiation (Fig. 5). The utilisation of available surface area in smaller
technologies is higher, thus they make more efﬁcient use of media.
Material expenditures can be reduced if smaller cell populations
are produced (such as those required for PCA and HTS analysis) if
smaller technologies are used. This is exhibited by a 39% reduction
in direct costs if T-75 ﬂasks are used as opposed to L-2 vessels for
the ﬁnal iPSC expansion stage at the HTS scale (Fig. 5a). However,
when satisfying the demands of PBP, the additional labour costs
incurred by the use of large numbers of units of smaller vessels
far outweigh the incremental reduction in material costs that such
technologies offer within the manual bioprocess. The COG per cell
line for the differentiation can be reduced by 76% if T-225 ﬂasks are
employed rather than T-25 ﬂasks (Fig. 5b). This is due to the reduc-
tion in the resultant labour costs associated with the use of T-225s.
Darker shades within each area of the matrices (Fig. 4) are illus-
trative of higher COG/cell line. Thus, the matrix also demonstrates
the economies of scale that can be achieved when the number of
cell lines produced per year increases. This is particularly true with
regards to automated processing (Fig. 4b), where a greater range in
the COG between different annual donor sample throughputs can
be observed than for the manual bioprocessing strategy.
A COG breakdown for the different equipment sizing conﬁg-PSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
urations available for use in the ﬁnal stage of expansion and
differentiation for the automated bioprocess strategy, whereby 107
iPSC-derived neurons are produced per cell line at a throughput of
s of the three analytical drug screening techniques (PCA, HTS & PBP) at a throughput
-derived neuron outputs per donor are shown in brackets on the x-axis. Maximum
en. Therefore for scales satisfying demands of PBP, direct costs beyond these values
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aig. 6. COG breakdown for possible equipment sizing conﬁgurations for an automa
t  a throughput of 50 cell lines/yr, whereby populations of 107 cells are produced 
ompacT SelecT automated processing equipment, i.e. 367% will require 4 Compac
0 cell lines per year is shown in Fig. 6. The use of smaller vessels,
uch as T-75s, necessitates the use of multiple CTS machines due to
he number of vessels required for such technologies, which corrob-
rates results described earlier (Fig. 4b), in that larger technologies
re preferred for this throughput in the optimal technology matrix.
his is particularly true of vessels used during differentiation, a
engthy process that occupies equipment capacity for long periods
f time. The optimal process conﬁguration, where the technologies
elected were 11 × T-75 ﬂasks for the ﬁnal iPSC expansion stage and
 × 5-F (5-layer T-ﬂask) for differentiation, results in a maximum
equirement of 1CTS machine. However, were T-75s and T-175s
o be used for the respective process steps above (as is optimal
or producing cells for HTS analysis), then 4CTS machines would
e required to produce cell populations satisfying the demands of
BP analysis. The latter of these options results in only an incre-
ental direct costs reduction (∼1%), whereas the resultant indirect
osts are 375% higher than the optimal process design. Larger tech-
ologies, which can house cell populations in a smaller number of
essels, are preferred as they do not have as signiﬁcant an impact
n automated processing equipment utilisation. Owing to the auto-
ated nature of this processing strategy, the use of multiple vessels
oes not impact signiﬁcantly upon labour costs, unlike manual pro-
essing, where it is important to minimise the number of units
equired in order to drive down labour costs.
Analysis of COG breakdowns for manual and automated biopro-
esses when the demands of HTS and PBP analysis at throughputs
f 50 and 100 cell lines per year are satisﬁed shows that auto-
ated processing can signiﬁcantly reduce labour costs associated
ith stem cell bioprocesses (Fig. 7). This is particularly due to addi-
ional ancillary tasks associated with manual bioprocess strategies,
uch as media changes and cell seeding and harvesting. Material
osts do not ﬂuctuate greatly between manual and automated pro-
essing. However, savings on the cost of labour are outweighed
y the additional indirect costs (a function of ﬁxed capital invest-
ent required) for the automated bioprocess when 50 cell linesPlease cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
re produced. A 10% COG per cell line reduction is offered by
anual processing when cells are produced for PBP analysis. At
 throughput of 100 cell lines per year, the additional indirect costs
ssociated with automated bioprocess strategies are spread acrossocess strategy for the ﬁnal iPSC expansion stage and differentiation unit operations
isfy the demands of PBP analysis. CTS utilisation refers to percentage utilisation of
T units. DC = direct costs. IDC = indirect costs.
enough cell lines to provide signiﬁcant COG reductions (19% at PBP
scale) against the manual bioprocess - the cost of which is heavily
weighted by labour costs. This is supported further by percentage
COG breakdowns for the manual and automated bioprocesses when
cell lines are produced to satisfy the demands of PBP analysis. At
higher annual throughputs, direct costs make up a higher percent-
age of the COG breakdown. For the automated bioprocess, direct
costs account for 41% of COG (70% for manual processing) when 50
cell lines are produced per year, compared to 58% (72% for manual
processing) if 100 cell lines are produced annually. This analysis
provides evidence that automation of patient-speciﬁc iPSC biopro-
cesses can provide signiﬁcant COG reductions at scales sufﬁcient to
warrant the additional capital expenditure. Indirect costs dominate
the COG breakdown for the automated bioprocess (Fig. 6) hence
minimisation of the number of pieces of automation equipment
must be achieved in order to curtail COGs.
There is no signiﬁcant reduction in either the labour costs or
material costs for both the manual and the automated bioprocess
at throughputs of 50 and 100 cell lines per year (Fig. 7). However,
when the process is scaled out, smaller COG ﬁgures are realised as a
result of reductions in the indirect costs per cell line. This suggests
that economies of scale can only be achieved for patient-speciﬁc
hiPSC bioprocesses requiring scale-out through shared use of ﬁxed
equipment. Bioprocess scheduling and equipment sizing in order
to maximise use of ﬁxed equipment and minimise the required size
of cleanrooms must therefore be considered during process design
in this area.
It can be concluded that a threshold throughput exists where
automated bioprocesses offer a COG reduction compared to a man-
ual bioprocesses. This is in accordance with previous studies in stem
cell bioprocess design [16]. When assessing the COG per cell line for
both the automated and manual bioprocess at throughputs ranging
from 50 to 200 cell lines, the point at which the automated biopro-
cess becomes more cost-effective than the manual bioprocess is at
a throughput of 65 cell lines (Fig. 8). The spike on the line represent-PSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
ing COG per cell line for automated bioprocesses also depicts the
throughput at which it is necessary to purchase additional auto-
mated processing equipment (a throughput of 110 cell lines). The
switchpoint identiﬁed between automated and manual processing
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Fig. 7. COG breakdown for manual and automated bioprocess strategies at throughputs of 50 and 100 cell lines, whereby populations of 107 cells are produced in order to
satisfy the demands of PBP. Percentage changes in COG/cell line caused by implementing an automated bioprocess strategy are shown above columns representing automated
bioprocess COG breakdowns.
Table 6
Probability distributions assigned to key bioprocess performance parameters in the stochastic Monte Carlo analysis of the manual and automated bioprocess strategies.
Parameter Probability distribution type Manual bioprocess probability
distribution proﬁle (min, most
likely, max)
Automated bioprocess
probability distribution proﬁle
(min, most Likely, max)
iPSC expansion harvest
yield
Triangular 75%, 90%, 95% 85%, 90%, 95%
iPSC  expansion harvest
density
Triangular 2.5 × 105, 3 × 105, 3.5 × 105 2.7 × 105, 3 × 105, 3.3 × 105
iPSC expansion fold Triangular 6.3, 7, 7.7 6.6, 7, 7.4
Differentiation
efﬁciency
Triangular 20%, 35%, 45% 30%, 35%, 40%
Differentiation harvest
yield
Triangular 80%, 90%, 95% 85%, 90%, 95%
Differentiation seeding
density
Triangular 0.8 × 104, 1 × 105, 1.1 × 105 0.9 × 105, 1 × 105, 1.1 × 105
Note: most likely values in the distribution proﬁles are taken from the base case scenario
F
1
a
c
c
wig. 8. COG per cell line at annual throughputs ranging from 50 to 200 cell lines of
07  iPSC-derived neurons for manual and automated processing.
re speciﬁc to the modelling assumptions made in this particularPlease cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
ase study.
The assumed cost of automation equipment is based upon the
urrent purchase cost for a functional CTS machine. At the time of
riting, this was the only piece of automation equipment that could from the deterministic bioprocess economics model.
fully support this bioprocess. In the future, other pieces of equip-
ment may  become available and competition may  drive down the
cost of automation equipment. The effect of the price of automation
equipment price on bioprocess COG can be seen in the Supplemen-
tary information accompanying this paper (Fig. S1).
4.1.2. Sensitivity analysis
In order to further identify key economic drivers associated with
the iPSC-derived bioprocess, and to provide further understanding
of where process development and optimisation resources might
be best focused, a sensitivity analysis was  carried out. Several pro-
cess and cost parameters were varied to reﬂect their best and worst
case values. The tool was  used to test the resultant change upon the
COG per cell line values that these variations. The Tornado charts
(Fig. 9) illustrate the effect on COG that variations in key param-
eters caused for (a) the manual bioprocess and (b) the automated
bioprocess at a throughput of 50 cell lines per year (where cell pop-
ulations that satisfy the demands of PBP are produced). The number
of iPSC expansion stages required was  the greatest economic driver
for both the manual and automated bioprocess strategies (Fig. 9).PSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
Variations in the number of iPSC expansion stages can occur due
to ﬂuctuations in key performance parameters. The impact of this
parameter upon COG can be signiﬁcant, as each additional iPSC
expansion stage necessitates additional direct resources and ﬁxed
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Fig. 9. Tornado plots showing the effect of variations in key parameters on COG for (a) the manual bioprocess strategy and (b) the automated bioprocess strategy at a
throughput of 50 cell lines/ year. Best case and Worst case values are shown in brackets on the y-axis labels.
Table 7
Key statistical parameters of the COG per cell line values for the manual and automated bioprocess strategies from the stochastic Monte Carlo analysis.
50 cell lines per year 100 cell lines per year
Manual bioprocess Automated bioprocess Manual bioprocess Automated bioprocess
e
s
C
b
b
b
p
c
d
l
(Mean () £64,841 £66,655 
Standard deviation £8481 £3025 
P  (COG < automated) 0.81 0.93 
quipment capacity. Thus, a change in the number of iPSC expan-
ion stages required within a bioprocess will signiﬁcantly affect
OG per cell line.
Labour costs are also a signiﬁcant cost driver for the manual
ioprocess, resulting in an 18% difference in COG between the
est and worst case scenarios. The fact that labour costs have
een identiﬁed as a key process economic driver is perhaps unsur-
rising; this parameter dominates the COG breakdown at high
ell line throughputs (see Fig. 7a). Similarly, the secondary costPlease cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
river for the automated bioprocess is FCI costs, which are the
argest contributor to the COG breakdown for this process strategy
Fig. 7b).£65,405 £48,601
£9493 £3221
0 0.89
4.2. Stochastic modelling
The mean COG/cell line value for the automated bioprocess is
higher than that of the manual bioprocess when producing 50 cell
lines per year, whereas at 100 cell lines per year, this value is higher
for the manual bioprocess, as described by the stochastic analysis
(Table 7). These ﬁgures are consistent with the deterministic model
results, which also show the same trend (Fig. 7).
The results of the Monte Carlo analysis (Table 7 and Fig. 10a andPSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
b) show that the standard deviation and range of COG values for
the automated bioprocess strategy at throughputs of both 50 and
100 cell lines per year (£3,025 (GBP) and £3,221 respectively) are
signiﬁcantly lower than those of the manual bioprocess strategy
ARTICLE ING ModelBEJ-6302; No. of Pages 14
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Fig. 10. Frequency distributions for the COG per cell line outputs for the automated
and manual bioprocess strategies under uncertainty when producing (a) 50 cell lines
per year and (b) 100 cell lines per year. (c) Relative frequency of the different number
of  iPSC expansion stages for the manual bioprocess strategy for 50 cell lines per year
superimposed onto the COG per cell line frequency distribution. Dashed lines depict
i
d
(
T
a
T
b
a
endividual COG per cell line outputs and continuous curves represent the frequency
istributions of the COG per cell line outputs.
£8,481 and £9,493 at 50 and 100 cell lines per year, respectively).
his suggests that the automated bioprocess is more robust from
 bioprocess economics standpoint than the manual bioprocess.Please cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
he frequency density curves and COG distributions (Fig. 10a and
) follow a distinct pattern. They are bimodal with a positive skew
nd hence the majority of COG values are concentrated at the lower
nd of the distribution and are followed by a long tail with a smaller PRESS
ring Journal xxx (2015) xxx–xxx 11
peak at the upper end of the distribution with higher COG values.
This is particularly true of the frequency distribution curves of the
manual bioprocess, where the peaks at the upper end of the distri-
bution where high COG values occur are larger compared to those
for the automated bioprocess. One explanation of the shape of the
frequency distributions can be illustrated in Fig. 10c, which shows
the relative frequency at which the number of iPSC expansion pas-
sages required for the manual bioprocess (at a throughput of 50 cell
lines per year) rises from six (as in the base case) to seven based on
process variability modelled in Monte Carlo analysis. The frequency
distribution of the COG per cell line for the manual bioprocess from
Fig. 10a is also displayed on Fig. 10c. This shows that the minor
peak with high COG values that appears in Fig. 10a and b is due
to the requirement of an additional stage of iPSC expansion owing
to process variations modelled during the Monte Carlo simulation.
Fig. 10c also emphasises the importance of minimising the number
of iPSC expansion stages as a strategy for minimisation of COG.
4.3. Can an acceptable COG for in-house manufacture of
patient-speciﬁc hiPSC derived cell lines be achieved?
List prices from vendors for a vial containing 106 non patient-
speciﬁc hPSC-derived cells currently lie in the region of US$
1000–2000. This study shows that, unlike non patient-speciﬁc stem
cell bioprocesses, where both direct and indirect cost savings can be
achieved on a per million cells basis via appropriate scale-up strate-
gies [16] economies of scale can only be achieved in patient-speciﬁc
cell lines through shared use of ﬁxed equipment. Direct costs per
cell line do not ﬂuctuate signiﬁcantly, regardless of throughput
(Fig. 7). The market price of patient-speciﬁc cell lines may  there-
fore be assumed to be higher than their non-speciﬁc counterparts;
not only because of the added expenditure as a result of scale-out
processing, but also the added analytical value provided by such
products in responder versus non-responder studies and potential
personalised medicine regimes (see Section 1). This is reﬂected in
the fact that patient-speciﬁc hPSC-derived cell lines are marketed
for ∼US$50k (∼£35k) for 107 cells, including the additional costs of
iPSC derivation and genetic engineering.
This case study reﬂects an in-house hiPSC-derived cell line man-
ufacturing regime. According to the stochastic modelling above, the
minimum COG per cell line that can be achieved is ∼£45,000. This is
signiﬁcantly higher than current market prices for such products. In
order for in-house production of cell lines for drug screening to be
worthwhile, an acceptable COG per cell line must be below current
market prices. A scenario analysis was  designed to identify the pro-
cess improvements required to reduce COG per cell line to below
£35,000. Within the scenario analysis, reductions in the indirect
costs and media costs have been assumed. A one-off new-build
facility has been assumed for this case study in order to capture
the ﬁxed equipment costs associated with manufacturing patient-
speciﬁc cell lines. In reality, such an in-house facility would likely
be used for multiple research activities. To reﬂect this, indirect costs
of 60% and 75% of the base case value have been investigated in this
analysis. Established Big Pharma companies might also make use
of existing experience in pharmaceutical reagent manufacturing in
order to produce media components and small molecules required
for certain unit operations in-house. This would allow some media
components to be produced at cost price, rather than purchasing
them at vendor list prices (as assumed in base case results). COG per
cell line at both base case media costs and a 25% reduction in media
costs have been modelled in this analysis. The process parame-
ters varied in this analysis were the differentiation efﬁciency andPSC bioprocessing for drug screening: Bioprocess economics and
015.09.024
iPSC expansion fold per stage. These parameters were chosen for
two reasons; primarily they both impact upon the number of iPSC
expansion stages required. This was identiﬁed as a key process eco-
nomics driver in the sensitivity analysis (Fig. 9). Secondly, advances
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Fig. 11. Contour plots showing windows of operation where COG  £35k/ cell line when (a) media cost = base scenario and IDC = 60% of base case values (b) media cost = 75%
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f  base case. Shaded areas on the plots show windows of operation whereby COG
OG  > £35 k/ cell line. IDC = indirect costs.
n media composition and morphogen delivery systems during iPSC
xpansion and differentiation are areas of concentrated research.
nnovations in these areas have proven that improvements in these
arameters are achievable on the base case values assumed in this
ase study [21,22,38–41].
The in-house scenario considered in this project was for a sin-
le drug screening project application and hence the indirect costs
ere only spread across this activity. In future it is possible to envis-
ge several drug screening applications where the investment is
ffset across several projects similar to how a vendor may  achieve
conomies of scale. Hence the impact of lowering the indirect costs
as explored. If indirect costs are 60% of base case value, there is
 large window of operation whereby a COG  £35k per cell line,
ven when media costs remain at the base case value (Fig. 11a).
ndeed, if the achievable iPSC expansion fold can be increased from
 to 10, then it would be acceptable for differentiation efﬁciency
o remain at 35%. If media costs could be reduced by 25%, then
 differentiation efﬁciency of 50% (up from 35% in the base case
cenario) would be required for COG  £35k per cell line, even if
he iPSC expansion fold could not be improved. The windows of
peration shrink signiﬁcantly at both base case and reduced media
ost values when indirect costs increase from 60% to 75% of the
ase case values (Fig. 11c and d). In this instance, improvements
n both differentiation efﬁciency and iPSC expansion to 76% and
1%, respectively, would be required. Less dramatic improvementsPlease cite this article in press as: M.  Jenkins, et al., Patient-speciﬁc hi
optimisation, Biochem. Eng. J. (2015), http://dx.doi.org/10.1016/j.bej.2
ould be necessary if media costs could be reduced by 25%. In this
nstance differentiation efﬁciencies as low as 52% and iPSC expan-
ion folds of 10 could allow COG  £35k per cell line to be achieved. IDC = 75% of base case values (d) media costs = 75% of base case value and IDC = 75%
5,000/cell line, white areas of the plots represent windows of operation whereby
The maximum indirect cost (% base case) whilst media costs remain
at base case value whereby a COG  £35k per cell line is still feasible
was found to be 77%. When media costs are 75% of the base case
values, this value increases to 81%. Both of these instances would
require improvements to produce a 12-fold expansion during iPSC
culture and a differentiation efﬁciency of 79%. Conversion of hiP-
SCs to neurons at efﬁciencies beyond 80% have been reported [41]
as have iPSC expansion folds of up to 11.3 over 7 days in planar
conditions, or up to 28 in bioreactor conditions [22,42] Therefore,
realising the windows of operation discussed above is not infeasi-
ble. In the event that ﬁxed capital investment (or indirect costs) can
be reduced by 25% or more there are realistic scenarios whereby in-
house manufacture of patient-speciﬁc, iPSC-derived cell lines could
be worthwhile for companies wishing to carry out responder versus
non-responder studies as part of drug development regimes. Lower
indirect cost values could be achieved by either retrospective ﬁtting
of an existing research facility, or by diversifying the functionality
of a new-build facility. The scenarios analysed above also illustrate
how changes to the bioprocess in terms of the key process param-
eters might impact upon COG and shows how the ﬁndings of this
study might be applied to bioprocesses other than the one that is
the focus of this work.
The scenarios examined here determine an acceptable COG to be
less than current market prices for patient-speciﬁc, hiPSC-derived
cell lines. This is because this case study examines production ofPSC bioprocessing for drug screening: Bioprocess economics and
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such cell lines for use in in-house studies. Were the cell lines dis-
cussed in this case study to be manufactured for sale, the acceptable
COG ﬁgure would be far lower in order to take into account COG as
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 percentage of sales. Smith (2010) determines this value to be in
he range of 40–60% for autologous products. It is possible to con-
lude that acceptable COG for patient-speciﬁc hiPSC-derived cell
ines designed for sale is in the region of £14,000–£21,000 per cell
ine (whereby 107 cells are produced for each line). It is assumed
hat a process producing cell lines for commercial sale would be
f a far greater scale than the bioprocess examined in this study
i.e. 100 cell lines per year). Identiﬁcation of process improvements
equired to reduce the COG derived in this study to such values is
herefore beyond the scope of this paper. However, future work
ill focus upon large-scale bioprocess design strategies in order to
aintain a supply chain of hPSC-derived cell lines to a number of
lients.
. Conclusion
A decisional tool is presented that consists of a bioprocess eco-
omics model with an integrated brute-force search algorithm. The
ool has been applied to an industrial case study, in which patient-
peciﬁc iPSC-derived neurons are produced for use in responder
ersus non-responder studies as part of the development of NCEs
o be used in personalised medicine regimes. Via the use of this
ool, optimal equipment sizing regimes were identiﬁed for both
 manual and an automated hPSC bioprocess. Furthermore, it can
e concluded that whilst the most cost-effective option of the two
rocess strategies tested is dependent on the throughput of the
rocess, the use of automation equipment was  found to result
n a more robust bioprocess in terms of COG values when tested
nder uncertainty. Indirect cost reductions are required in order to
chieve acceptable manufacturing COG. This might be done by ret-
ospectively ﬁtting existing facilities, or diversifying functionality
f a new-build facility in order to offset some of the required ﬁxed
apital investment to other projects. Were an existing full-scale
rocess to be adapted from a manual to an automated bioprocess
t would be wise to take into account the cost and time required to
rain staff to use automated equipment. Furthermore, the logistics
nd costs of updating facility infrastructure to cope with automated
rocessing should be considered in the case of retro-ﬁtting an exist-
ng facility. This work modelled a relatively small scale bioprocess
n commercial terms. However, the outputs can be of use in aiding
ecision making early on in bioprocess design for patient-speciﬁc
ell line production at a variety of scales. Expanding the deci-
ional tool presented here to account for larger scale bioprocesses,
ncluding the production of cells for autologous and allogeneic cell
herapies will be the focus of future work.
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